Results 51 to 60 of about 1,974 (156)

SMYD3 Modulates AMPK-mTOR Signaling Balance in Cancer Cell Response to DNA Damage

Cells, 2023
Cells respond to DNA damage by activating a complex array of signaling networks, which include the AMPK and mTOR pathways. After DNA double-strand breakage, ATM, a core component of the DNA repair system, activates the AMPK-TSC2 pathway, leading to the ...
Martina Lepore Signorile, Paola Sanese, Elisabetta Di Nicola, Candida Fasano, Giovanna Forte, Katia De Marco, Vittoria Disciglio, Marialaura Latrofa, Antonino Pantaleo, Greta Varchi, Alberto Del Rio, Valentina Grossi, Cristiano Simone   +12 more
doaj   +1 more source

SMYD3 (SET and MYND domain containing 3) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on SMYD3 (SET and MYND domain containing 3), with data on DNA, on the protein encoded, and where the gene is implicated.
Luo, XG, Guo, S, Zhang, TC
openaire   +2 more sources

Discovery of Isoxazole Amides as Potent and Selective SMYD3 Inhibitors

ACS Medicinal Chemistry Letters, 2019
We report herein the discovery of isoxazole amides as potent and selective SET and MYND Domain-Containing Protein 3 (SMYD3) inhibitors. Elucidation of the structure-activity relationship of the high-throughput screening (HTS) lead compound 1 provided potent and selective SMYD3 inhibitors.
Dai-Shi Su, Junya Qu, Mark Schulz, Chuck W. Blackledge, Hongyi Yu, Jenny Zeng, Joelle Burgess, Alexander Reif, Melissa Stern, Raman Nagarajan, Melissa Baker Pappalardi, Kristen Wong, Alan P. Graves, William Bonnette, Liping Wang, Patricia Elkins, Beth Knapp-Reed, Jeffrey D. Carson, Charles McHugh, Helai Mohammad, Ryan Kruger, Juan Luengo, Dirk A. Heerding, Caretha L. Creasy   +23 more
openaire   +3 more sources

SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer [PDF]

Nature, 2014
Deregulation of lysine methylation signalling has emerged as a common aetiological factor in cancer pathogenesis, with inhibitors of several histone lysine methyltransferases (KMTs) being developed as chemotherapeutics. The largely cytoplasmic KMT SMYD3 (SET and MYND domain containing protein 3) is overexpressed in numerous human tumours.
Mazur, Pawel, Reynoird, Nicolas, Khatri, Purvesh, Jansen, Pascal, Wilkinson, Alex, Liu, Shichong, Barbash, Olena, van Aller, Glenn, Huddleston, Michael, Dhanak, Dashyant, Tummino, Peter, Kruger, Ryan, Garcia, Benjamin, Butte, Atul, Vermeulen, Michiel, Sage, Julien, Gozani, Or   +16 more
openaire   +5 more sources

Structural and Functional Profiling of the Human Histone Methyltransferase SMYD3

PLoS ONE, 2011
The SET and MYND Domain (SMYD) proteins comprise a unique family of multi-domain SET histone methyltransferases that are implicated in human cancer progression. Here we report an analysis of the crystal structure of the full length human SMYD3 in a complex with an analog of the S-adenosyl methionine (SAM) methyl donor cofactor.
Kenneth W Foreman, Mark Brown, Frances Park, Spencer Emtage, June Harriss, Chhaya Das, Li Zhu, Andy Crew, Lee Arnold, Salam Shaaban, Philip Tucker   +10 more
openaire   +4 more sources

Conservation Status of Two Italian Local Poultry Breeds: Faraona Camosciata and Oca Padovana

Animal Genetics, Volume 57, Issue 3, June 2026.
ABSTRACT The present study aimed to assess the conservation status and characterize the phenotypic and genomic diversity of two endangered Italian poultry genetic resources to guide their conservation plans. Blood samples and morphometric data were collected on 50 Faraona Camosciata (FAC, Numida meleagris) and 50 Oca Padovana (OPD, Anser anser) adult ...
Filippo Cendron, Enrico Bortoletto, Francesco Perini, Maristella Baruchello, Umberto Rosani, Emiliano Lasagna, Martino Cassandro, Mauro Penasa   +7 more
wiley   +1 more source

SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer

Cells, 2023
Gastric cancer (GC) is the third most deadly cancer worldwide. Considerable efforts have been made to find targetable drivers in order to improve patient outcomes.
Katia De Marco, Martina Lepore Signorile, Elisabetta Di Nicola, Paola Sanese, Candida Fasano, Giovanna Forte, Vittoria Disciglio, Antonino Pantaleo, Greta Varchi, Alberto Del Rio, Valentina Grossi, Cristiano Simone   +11 more
doaj   +1 more source

Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora

Marine Drugs, 2020
Chitooligosaccharides (COS) have a variety of biological activities due to their positively charged amino groups. Studies have shown that COS have antidiabetic effects, but their molecular mechanism has not been fully elucidated.
Qiutong Wang, Yajie Jiang, Xuegang Luo, Chang Wang, Nan Wang, Hongpeng He, Tongcun Zhang, Liehuan Chen   +7 more
doaj   +1 more source

Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma

The Tohoku Journal of Experimental Medicine, 2017
SET and MYND domain-containing protein 3 (SMYD3) is a kind of histone lysine methyltransferase, responsible for transcriptional activation as a member of an RNA polymerase complex. The ectopic expression of SMYD3 is proved to promote the progress of many kinds of cancers.
Fei, Xiao, Ma, Yun, Liu, Xiaowei, Meng, Zhixin   +3 more
openaire   +3 more sources

RNA‐Binding Proteins and Ferroptosis in Cancer: Mechanism and Therapeutic Implications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ferroptosis critically influences cancer cell fate and represents a promising therapeutic strategy. Emerging evidence identifies RNA‐binding proteins (RBPs) as key post‐transcriptional regulators of ferroptosis. The figure summarizes ferroptosis‐related RBPs across cancers: blue RBPs act as tumor suppressors by promoting ferroptosis, whereas red RBPs ...
Linlin Chang, Bin Lu, Haotian Shang, Wanjing Ding, Chunhua Wei, Xiaotian Qi, Pengxing He   +6 more
wiley   +1 more source